Mallinckrodt reported that all primary and secondary outcome measures were met in its Phase IV study of Acthar Gel (repository corticotropin injection) in persi 13 June 2019
Convincing physicians that their drug is a better option than AbbVie’s Humira has been an aim of a lot of companies at the EULAR congress again this year – with 13 June 2019
The chance to persuade European rheumatologists and other healthcare practitioners to switch to or prescribe from the outset their anti-TNF biosimilars make EUL 12 June 2019
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the 7 June 2019
Conference attendees gathered in the cavernous RAI Amsterdam convention center last week to hear the latest data from a therapy area valued at around $44 billio 22 June 2018
There is more activity on the biosimilars front at annual meeting of the European Congress of Rheumatology (EULAR), the leading conference in this therapy area, 15 June 2018
Small molecule and biologic go head to head at the Annual European Congress of Rheumatology (EULAR) in Amsterdam on Friday morning, with oral presentations from 15 June 2018
The US-based generics arm of Novartis will present data from two long-term, Phase III studies of its biosimilar rheumatoid arthritis therapies at the Annual Eur 15 June 2018
In an oral presentation to be given at the annual meeting of the European League Against Rheumatism (EULAR), US-based Celgene will present a post hoc analysis o 14 June 2018
Belgian drugmaker UCB (Euronext Brussels: UCB) has presented striking Phase IIb data for its experimental therapy bimekizumab, an IL17 blocker, at the ongoing E 14 June 2018
In an increasingly crowded anti-TNF market, Germany’s Boehringer Ingelheim believes that clinical data is key to differentiating its products and gaining market 20 June 2017
On the penultimate day of the Annual European Congress of Rheumatology (EULAR), Britain's largest pharma company GlaxoSmithKline has provided data from a ten ye 16 June 2017
Authorities in Denmark have put together a program designed to allay patient’s concerns over switching to biosimilars, in collaboration with the Danish Rheumati 16 June 2017
With regulatory approval for a broader label pending in the USA, Eli Lilly as released more data on psoriatic arthritis candidate Taltz (ixekizumab) supporting 16 June 2017
Eli Lilly (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) have announced new data from eight Olumiant (baricitinib) clinical trials at EULAR, the Annual Europ 16 June 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.